Table 3.
Multivariable analysis of progression-free survival.
| Predictor | Hazard ratio | 95% CI | P-value | |
|---|---|---|---|---|
| Lower | Upper | |||
| TMT median | ||||
| > 6.24 mm vs. ≤ 6.24 mm | 0.399 | 0.209 | 0.7633 | 0.005* |
| cT category | ||||
| T2 vs. T1 | 1.576 | 0.503 | 4.936 | 0.435 |
| T3 vs. T1 | 1.973 | 0.599 | 6.505 | 0.264 |
| T4 vs. T1 | 2.236 | 0.7332 | 6.8156 | 0.157 |
| cN category | ||||
| N1 vs. N0 | 1.178 | 0.474 | 2.927 | 0.724 |
| N2 vs. N0 | 2.083 | 0.819 | 5.296 | 0.123 |
| N3 vs. N0 | 3.533 | 1.099 | 11.356 | 0.034* |
| cM category | ||||
| M1 vs. M0 | 2.535 | 0.878 | 7.318 | 0.085 |
| Overall stage | ||||
| II vs. I | 0.729 | 0.193 | 2.745 | 0.639 |
| III vs. I | 0.904 | 0.249 | 3.285 | 0.878 |
| IV vs. I | 1.031 | 0.254 | 4.183 | 0.967 |
CI confidence interval, TMT temporalis muscle thickness, cT clinical tumor, cN clinical node, cM clinical metastasis.
*P value less than 0.05 indicates statistical significance.